Northwest & Ethical Investments L.P. Makes New $3.18 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Northwest & Ethical Investments L.P. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,400 shares of the medical research company’s stock, valued at approximately $3,175,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA during the third quarter worth $147,683,000. 1832 Asset Management L.P. increased its holdings in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of IQVIA during the second quarter worth $70,610,000. Finally, Impax Asset Management Group plc increased its holdings in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Friday, November 1st. Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Leerink Partners restated an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

IQV stock opened at $201.43 on Friday. The stock has a market capitalization of $36.56 billion, a PE ratio of 26.43, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. The company’s 50-day moving average is $219.50 and its 200-day moving average is $226.40. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.